Percutaneous Cryoablation of Ovarian Cancer Metastasis to the Liver

Gao, Wei; Guo, Zhi; Zhang, Xuening; Wang, Ying; Zhang, Weihao; Yang, Xueling; Yu, Haipeng

doi:10.1097/igc.0000000000000420

Cited by 21 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our technical success rate of 94.6%, technique efficacy rate of 89.5% at 3 months, and local tumor progression rate of 23.3% compare favorably to the limited previously published data for percutaneous cryoablation of liver metastases, with technical success rates of 83 92% and technique efficacy rates of 47–85.4% [12, 18, 35, 36]. Previous studies of percutaneous cryoablation of HCC have reported technical success rates of 51–98.5% and technique efficacy rates of 69 75.8% [16, 22, 34].…”

Section: Discussionsupporting

confidence: 85%

“…For these reasons, cryoablation has been favored by some to treat hepatic masses, particularly those that are close to critical structures, such as the diaphragm, chest wall, heart, lung, gallbladder, and biliary tree [24, 33]. The majority of experience with percutaneous image-guided cryoablation has been in the treatment of HCC [16, 19, 22, 34] and, to a lesser extent, metastases [12, 19, 35]. However, to our knowledge, the overall safety and efficacy of percutaneous image-guided percutaneous cryoablation has not been defined in patients with a variety of primary and secondary hepatic tumors in a series using both CT and MRI guidance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes

Glazer

Tatlı

Shyn

et al. 2017

American Journal of Roentgenology

View full text Add to dashboard Cite

OBJECTIVE The purpose of this article is to report our intermediate to long-term outcomes with image-guided percutaneous hepatic tumor cryoablation and to evaluate its technical success, technique efficacy, local tumor progression, and adverse event rate. MATERIALS AND METHODS Between 1998 and 2014, 299 hepatic tumors (243 metastases and 56 primary tumors; mean diameter, 2.5 cm; median diameter, 2.2 cm; range, 0.3–7.8 cm) in 186 patients (95 women; mean age, 60.9 years; range, 29–88 years) underwent cryoablation during 236 procedures using CT (n = 126), MRI (n = 100), or PET/CT (n = 10) guidance. Technical success, technique efficacy at 3 months, local tumor progression (mean follow-up, 2.5 years; range, 2 months to 14.6 years), and adverse event rates were calculated. RESULTS The technical success rate was 94.6% (279/295). The technique efficacy rate was 89.5% (231/258) and was greater for tumors smaller than 4 cm (93.4%; 213/228) than for larger tumors (60.0%; 18/30) (p < 0.0001). Local tumor progression occurred in 23.3% (60/258) of tumors and was significantly more common after the treatment of tumors 4 cm or larger (63.3%; 19/30) compared with smaller tumors (18.0%; 41/228) (p < 0.0001). Adverse events followed 33.8% (80/236) of procedures and were grade 3–5 in 10.6% (25/236) of cases. Grade 3 or greater adverse events more commonly followed the treatment of larger tumors (19.5%; 8/41) compared with smaller tumors (8.7%; 17/195) (p = 0.04). CONCLUSION Image-guided percutaneous cryoablation of hepatic tumors is efficacious; however, tumors smaller than 4 cm are more likely to be treated successfully and without an adverse event.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes

Glazer

Tatlı

Shyn

et al. 2017

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…19 Studies from 2009 onward have demonstrated an improvement in disease-free survival and total survival of patients undergoing hepatic metastasectomy regardless of the types of primary neoplasias. 7,9,[20][21][22][23][24][25] Based on previous studies, the mean total survival for patients with stage IV ovarian epithelial cancer varied between 15 and 29 months, with a total survival of 20% at 5 years. 18 In the current study, diseasefree survival was better in patients with peritoneal seeding metastasis; however this result was nonsignificant and the overall survival analysis showed no difference among these patients.…”

Section: Discussionmentioning

confidence: 99%

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer

Luna‐Abanto

Ruiz

Martínez

et al. 2020

Journal of Gynecologic Surgery

View full text Add to dashboard Cite

Objective: The aim of this study was to describe and evaluate the safety of hepatic resections for ovarian cancer liver metastases and the benefit in terms of survival as part of cytoreductive surgery among peritoneal seeding and parenchymal metastases. Materials and Methods: Data were reviewed retrospectively from patients who underwent liver resection as part of cytoreductive surgery for ovarian cancer at the Instituto Nacional de Enfermedades Neoplásicas, in Lima, Perú, patients underwent surgical cytoreduction for ovarian cancer; 39 of these patients had liver resection as part of their surgical treatment, with 9, 17, and 13 patients receiving primary, secondary, and tertiary, resections, respectively. The mean age of the patients was 46, the majority (87%) had stage III/IV ovarian cancer. In addition, 21 patients had parenchymal metastasis resections, and 95% of the patients had Dindo-Clavien I and II grade complications. The 30-day mortality rate was 0. Conclusions: Liver resection for advanced ovarian cancer is a safe procedure for primary up to quaternary cytoreduction and may confer survival benefits to patients. ( J GYNECOL SURG 36:70)

show abstract

“…Survival rate after the first session of TACE was 58% at 1 year, 19% at 2 years, and 13% at 3 years. Recently, Gao et al 23 reported cryoablation in the treatment of patients with liver metastasis from OC. The LTP rate after ablation was 7.14%, and 1-year OS rate was 92.3%.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound-Guided Percutaneous Radiofrequency Ablation of Liver Metastasis From Ovarian Cancer: A Single-Center Initial Experience

Liu¹,

Huang²,

Jiang³

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Percutaneous Cryoablation of Ovarian Cancer Metastasis to the Liver

Abstract: Our initial experience showed that cryoablation is a safe and effective ablative therapy, providing a high rate of local tumor control in ovarian cancer liver metastases.

Cited by 21 publications

References 24 publications

Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes

Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer

Ultrasound-Guided Percutaneous Radiofrequency Ablation of Liver Metastasis From Ovarian Cancer: A Single-Center Initial Experience

Contact Info

Product

Resources

About